SAN DIEGO - Sept. 21, 2004 - A new report by prominent biowarfare experts cites the technology of San Diego-based Aethlon Medical, Inc. (OTCBB: AEMD) as a new potential weapon in America's defenses against bioterrorism.
The report, authored by Dr. Kenneth Alibek, the Executive Director of Education for the National Center for Biodefense at George Mason University (NCBD) and by Dr. Charles Bailey, the NCBD's Executive Director of Research, calls the company's Hemopurifier(TM) cartridge potentially "an effective weapon that could be rapidly deployed even against genetically altered biowarfare agents."
The report examines the state of the current and potential biowarfare threats facing our country and discusses the limitations of the treatment options currently available in the event of an attack.
In their report, Alibek and Bailey discuss the potential of Aethlon's Hemopurifier cartridges to bind a wide variety of pathogenic enveloped viruses, including some hemorrhagic fever viruses that have already been weaponized and for which there is no effective treatment. The report says the Hemopurifier technology "can be rapidly made, tested, and deployed to remove new, resistant strains of biological warfare agents from soldiers and civilians."
According to the report, "Aethlon clearly fills a large void in the armamentarium of available treatments for several organisms that may be released either as 'natural' epidemics or deliberately as weapons of bioterror."
The full report is available on the Aethlon website at www.aethlonmedical.com.
The company is pursuing federal government funding under Project Bioshield, a $5.6 billion program which the President signed into law on July 21, for further development of the Hemopurifier cartridge. In preclinical human blood studies, it has already demonstrated its ability to effectively remove HIV (the AIDS Virus), HCV (Hepatitis C Virus), and related protein toxins from infected blood.
Information about Aethlon Medical, Inc.
Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopruifier technology is available at www.aethlonmedical.com.
Ken Alibek M.D., Ph.D., D.Sc.
Dr. Alibek is the Executive Director of Education at the National Center for Biodefense at George Mason University (GMU), and is a Distinguished Professor at GMU as well. Dr. Alibek specializes in medical and scientific research dedicated to developing new forms of protection against biological weapons and other infectious diseases. Formerly, Dr. Alibek was a Soviet Army Colonel, and served as First Deputy Chief of the civilian branch of the Soviet Union's biological weapons program until he defected to the United States in 1992 and subsequently served as a consultant to numerous U.S. government agencies in the areas of medical microbiology, biological weapons defense, and biological weapons nonproliferation. Dr. Alibek has worked with the National Institutes of Health, testified extensively before the U.S. Congress on nonproliferation of biological weapons and is the author of Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World--Told from Inside by the Man Who Ran It, published by Random House Books. He holds numerous patents, is widely published in science journals, and has provided over 300 lectures and presentations to military and civilian universities, as well as foreign governments. The December 2003 issue of the Acumen Journal of Life Sciences named Dr. Alibek as one of top five biological warfare experts in the nation.